Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 25;7:225. doi: 10.3389/fpls.2016.00225

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Kilgore, Augustin, May, Crow and Kutchan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Chromatographic separation and MS/MS analysis of the primary 4′-O-methylnorbelladine products (10bS,4aR)- and (10bR,4aS)-noroxomaritidine. The enantiomers (10bS,4aR)- and (10bR,4aS)-noroxomaritidine were chromatographically separated with a chiral-CBH column and analyzed by MS/MS using an enhanced product ion (EPI) scan. (A) Samples, top to bottom: (10bR,4aS)- and (10bS,4aR)-noroxomaritidine standard, CYP96T1 assay, CPR assay, CYP96T1 assay without 4′-O-methylnorbelladine substrate and no Sf9 cells assay. (B) EPI fragmentation pattern for enantiomer 1 of (10bR,4aS)- and (10bS,4aR)-noroxomaritidine. (C) EPI fragmentation pattern for enantiomer 2 of (10bR,4aS)- and (10bS,4aR)-noroxomaritidine. (D) EPI fragmentation pattern for enantiomer 1 in the CYP96T1 assay with 4′-O-methylnorbelladine as substrate. (E) EPI fragmentation pattern for enantiomer 2 in the CYP96T1 assay with 4′-O-methylnorbelladine as substrate. Intensity is presented in counts per second (CPS).